Mereo BioPharma Group plc Director Dealing (1507V)
2020年8月5日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMMPH
RNS Number : 1507V
Mereo BioPharma Group plc
05 August 2020
Mereo BioPharma Group plc
Notification of Director Dealing
London and Redwood City, Calif ., August 5, 2020 - Mereo
BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the
Company", a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, received notification that on July 31
2020 Denise Scots-Knight, Chief Executive Officer of Mereo,
purchased 10,563 American Depositary Shares (ADSs) at a price of
USD 2.85 per ADS.
The below announcement and notification is made in accordance
with the EU Market Abuse Regulation. The form required under the EU
Market Abuse Regulation follows.
1 Details of the person discharging managerial responsibilities
a) Name Denise Scots-Knight
------------------------ ----------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------ ----------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ ----------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------
a) Description of MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY
the financial SHARES (ADSs)
instrument, type
of instrument
and identification
code
------------------------ ----------------------------------------------
b) Nature of the PURCHASE
transaction
------------------------ ----------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) USD 2.85 10,563
----------
------------------------ ----------------------------------------------
d) Aggregated information:
volume, Price
------------------------ ----------------------------------------------
e) Date of the transaction 2020-07-31
------------------------ ----------------------------------------------
f) Place of the XNMS
transaction
------------------------ ----------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLZLLBBVLZBBK
(END) Dow Jones Newswires
August 05, 2020 02:00 ET (06:00 GMT)
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 11 2024 まで 12 2024
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Mereo Biopharma Group Plc (ロンドン証券取引所): 0 recent articles
その他のMereo Biopharma Group Plcニュース記事